Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Publication of Circular and RTW Bio Prospectus
Publication of Circular and RTW Bio Prospectus
Publication of Circular and RTW Bio Prospectus
Update regarding timing of Proposed Scheme of Reconstruction
Update regarding timing of Proposed Scheme of Reconstruction
Update regarding timing of Proposed Scheme of Reconstruction
Unaudited NAV for November 2023
Unaudited NAV for November 2023
Unaudited NAV for November 2023
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
Unaudited NAV for October 2023
Unaudited NAV for October 2023
Unaudited NAV for October 2023
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Unaudited NAV for September 2023
Unaudited NAV for September 2023
Unaudited NAV for September 2023
Interim Results for the Six Months Ended 30 June 2023
Interim Results for the Six Months Ended 30 June 2023
Interim Results for the Six Months Ended 30 June 2023
Board Change
Board Change
Board Change
EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad leads the follow-on financing for the BBQ brand Burnhard
EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad leads the follow-on financing for the BBQ brand Burnhard
EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad leads the follow-on financing for the BBQ brand Burnhard
Notice of Results and Investor Presentation
Notice of Results and Investor Presentation
Notice of Results and Investor Presentation
Unaudited NAV for August 2023
Unaudited NAV for August 2023
Unaudited NAV for August 2023
EQS-News: Heliad invests in artificial intelligence business AI21 Labs
EQS-News: Heliad invests in artificial intelligence business AI21 Labs
EQS-News: Heliad invests in artificial intelligence business AI21 Labs
Unaudited NAV for July 2023
Unaudited NAV for July 2023
Unaudited NAV for July 2023
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Arix Announces Strategic Review
Arix Announces Strategic Review
Arix Announces Strategic Review
Unaudited NAV for June 2023
Unaudited NAV for June 2023
Unaudited NAV for June 2023
Portfolio company Disc Medicine raises $157.8 million in public offering
Portfolio company Disc Medicine raises $157.8 million in public offering
Portfolio company Disc Medicine raises $157.8 million in public offering
EQS-Adhoc: Heliad Equity Partners GmbH & Co. KGaA: Merger of Heliad Equity Partners GmbH & Co. KGaA into FinLab AG: Mutual Understanding on exchange ratio
EQS-Adhoc: Heliad Equity Partners GmbH & Co. KGaA: Merger of Heliad Equity Partners GmbH & Co. KGaA into FinLab AG: Mutual Understanding on exchange ratio
EQS-Adhoc: Heliad Equity Partners GmbH & Co. KGaA: Merger of Heliad Equity Partners GmbH & Co. KGaA into FinLab AG: Mutual Understanding on exchange ratio
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA